Differences in PROs found in CORRONA(now CorEvitas) PsA/SpA registry Ax-PsA and AxSpA patients. Can we better use PROs for disease characterization/differentiation? Abstract #OP0049 #EULAR2021 @RheumNow https://t.co/uHW2FQe0A5 https://t.co/HuPPUTAC9Z

• https://ard.bmj.com/content/80/Suppl_1/26.1

Plenary abstract #OP0010: Fecal microbiota transplant (FMT) found to be inferior to sham in treating active peripheral PsA. No SAEs in patients treated with FMT. @RheumNow #EULAR2021 https://t.co/a5HgrJ4y1C https://t.co/Jk9FQZdn4B

• https://ard.bmj.com/content/80/Suppl_1/6.full

Does Fecal transplant work to treat PsA? per FLORA trial: No benefits from fecal microbiotia transplantation vs sham in PsA w/ active dz despite MTX (limited by small size, high placebo response) - Dr. M Kragsnaes Abstr#OP0010 #EULAR2021 @rheumnow https://t.co/I7PsWgK9uA https://t.co/OKC4QcH8Nq

• https://ard.bmj.com/content/early/2021/04/28/annrheumdis-2020-219511

The post hoc EXCEED analysis showed similar efficacy of SEC and ADA with respect to enthesitis burden in PsA patients. #EULAR2021 @RheumNow Poster #POS0194 https://t.co/FaIZ7LcoNj

The post hoc EXCEED analysis showed similar efficacy of SEC and ADA with respect to enthesitis burden. What drug class do you choose as first line therapy for your PsA patients with prominent enthesitis? #EULAR2021 @RheumNow

Dr. Angioni et al characterize PsA clinical remission on a molecular level. c-FOS and CCD50 (YMER) appear to be two key genes. #EULAR2021 poster #POS0409 @RheumNow https://t.co/4lytsgjdzj https://t.co/ySjIXBHTA0

• Module

Hands-Down Rheumatology - Gout doesnt get to the hands until its done its damage below (MTP, ankle, knee) and usually only in those with severe tophaceous goutdCan also present as dactylitis or Carpal tunnel. Women on diuretics w/ CKD can get gout in Nodal OA joints https://t.co/EpBpdC31J6